Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms

DOI: 10.1111/j.1439-0272.2011.01268.x
Andrologia, 2012, 44 Suppl 1, 791-5.

#	Paper	IF	Citations
18	Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck. *Journal of Sexual Medicine*, **2012**, 9, 2293-306	1.1	41
17	Phosphodiesterase-5 expression and function in the lower urinary tract: a critical review. *Urology*, **2013**, 81, 480-7	1.6	12
16	Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia. *Pharmacotherapy*, **2013**, 33, 639-49	5.8	16
15	Current world literature. *Current Opinion in Urology*, **2013**, 23, 95-103	2.8	
14	Management of benign prostatic hyperplasia: role of phosphodiesterase-5 inhibitors. *Drugs and Aging*, **2014**, 31, 425-39	4.7	10
13	Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and □adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH. *Asian Journal of Andrology*, **2015**, 17, 1022-32	2.8	15
12	Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. *European Urology*, **2017**, 71, 570-581	10.2	36
11	Medical management of benign prostatic hyperplasia. **2018**, 509-525		
10	Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. *World Journal of Urology*, **2019**, 37, 143-153	4	9
9	Systematic Review of Combination Drug Therapy for Non-neurogenic Lower Urinary Tract Symptoms. *European Urology*, **2019**, 75, 129-168	10.2	12
8	Combination Therapy with Alpha-blocker and Phosphodiesterase-5 Inhibitor for Improving Lower Urinary Tract Symptoms and Erectile Dysfunction in Comparison with Monotherapy: A Systematic Review and Meta-analysis. *European Urology Focus*, **2020**, 6, 537-558	5.1	14
7	Efficacy and tolerability of combination therapy with alpha-blockers and phosphodiesterase-5 inhibitors compared with monotherapy for lower urinary tract symptoms: Protocol for a systematic review and network meta-analysis. *Medicine (United States)*, **2020**, 99, e22834	1.8	2
6	Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis. *Therapeutic Advances in Urology*, **2021**, 13, 1756287221993283	3.2	0
5	The effect of pharmacotherapy on prostate volume, prostate perfusion and prostate-specific antigen (prostate morphometric parameters) in patients with lower urinary tract symptoms and benign prostatic obstruction. A systematic review and meta-analysis. *Central European Journal of Urology*, **2021**, 74, 388-421	0.9	0
4	Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on □Blockers and 5-Alpha Reductase Inhibitors. *Uro*, **2021**, 1, 82-98		
3	Systematic Review of Oral Combination Therapy for Erectile Dysfunction When Phosphodiesterase Type 5 Inhibitor Monotherapy Fails. *Sexual Medicine Reviews*, **2019**, 7, 430-441	5.6	13
2	Comparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis. *PLoS ONE*, **2014**, 9, e107593	3.7	33

1	Study of phosphodiesterase 5 inhibitors and □adrenoceptor antagonists used alone or in combination for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. *Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology*, **2020**, 72, 13-21	4.4	9